Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.

@article{MoraPeris2013PharmacokineticPA,
  title={Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.},
  author={Borja Mora-Peris and Adam Croucher and Laura Jayne Else and Jaime H Vera and Saye Khoo and George Scullard and David Back and A Thomas Winston},
  journal={The Journal of antimicrobial chemotherapy},
  year={2013},
  volume={68 6},
  pages={1348-53}
}
BACKGROUND Once-daily nucleoside-sparing combination antiretroviral therapy regimens are attractive options for the treatment of HIV infection. However, the pharmacokinetic profiles of such regimens are often not established. METHODS HIV-infected subjects receiving 245/200 mg of tenofovir/emtricitabine plus 800/100 mg of darunavir/ritonavir once daily with plasma HIV RNA <50 copies/mL were eligible. On day 1 (period 1), 150 mg of maraviroc daily was added and on day 11 (period 2), tenofovir… CONTINUE READING

From This Paper

Topics from this paper.